Drugs / Bovhyaluronidase azoximer
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT06383819 | Apr 2022 → Dec 2023 | long COVID-19, polymyositis, pulmonary fibrosis | NPO Petrovax | Completed | Missed primary |
| Phase not applicable1 trial | ||||||
| — | NCT06568718 | Mar 2023 → Feb 2024 | benign prostatic hyperplasia | NPO Petrovax | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 22
| Date | Issuer | Release |
|---|---|---|
| 2026-06-26 | NPO Petrovax | Results A Study Evaluating Longidaza® Published in Urologia Journal: Combination Treatment Reduced the Risk of Chronic Prostatitis Recurrence Nearly Fourfold petrovax.com ↗
Results of a study conducted by Russian researchers and published in Urologia Journal [ 1 ] demonstrate that targeting bacterial biofilms can significantly improve treatment outcomes and reduce the risk of disease recurrence by nearly fourfold. |
| 2026-06-17 | NPO Petrovax | Results A Russian compound becomes the first in the world to demonstrate a significant improvement of exercise tolerance among patients with post-COVID lung injury in a multicenter randomized controlled trial petrovax.com ↗
By Day 71, the proportion of patients experiencing exercise-induced oxygen desaturation had decreased by 61% compared with placebo (p = 0.006). |
| 2026-03-26 | NPO Petrovax | Results At the EAU Congress in London, experts presented data on the potential of Longidaza in restoring male fertility after COVID-19 petrovax.com ↗
Russian scientists highlighted how Longidaza ® , a product developed in Russia and used as part of combination treatment, may help improve the reproductive health of men suffering from post-COVID complications. |
| 2025-04-01 | NPO Petrovax | Results Russian scientists present successful experience in managing prostatitis at the congress in Madrid petrovax.com ↗ |
| 2024-12-18 | NPO Petrovax | Results Bovhyaluronidase azoximer significantly reduces exercise intolerance in patients with long-term pulmonary sequelae of COVID-19 petrovax.com ↗
Longidaza demonstrated a statistically significant 62% reduction in the proportion of patients with exertional desaturation (OR = 0.35, p = 0.0051) and a 27% reduction in the proportion of patients exhibiting exertional dyspnea (OR = 0.62, p = 0.043) by Day 71 compared to placebo. |
| 2024-11-12 | NPO Petrovax | Results Original drug Longidaza® presented in China petrovax.com ↗
The therapy with this unique Russian molecule helps reduce dyspnea, increases forced vital capacity of the lungs, and improves exercise tolerance [ 1 ] . |
| 2024-10-30 | NPO Petrovax | Results Modern treatment methods help to prolong and improve the lives of comorbid patients petrovax.com ↗
Long-Cov-III-21 study [ 2 ] demonstrated that the drug increased the proportion of patients with a 10% increase in forced vital capacity, and also helped reduce the occurrence of common post-Covid symptoms such as fatigue and malaise after exercise. |
| 2024-09-17 | NPO Petrovax | Results New study explores Longidaza-supplemented BPH combination therapy petrovax.com ↗
A combination therapy with Longidaza ® and alpha blockers has demonstrated significant improvement in treatment outcomes for benign prostatic hyperplasia (BPH). |
| 2024-09-11 | NPO Petrovax | Results Successfully fighting against abnormal scarring: experts present new research at Adverse Event Congress petrovax.com ↗
Longidaza and Imoferaza have demonstrated significant improvement in scar condition. |
| 2024-06-24 | NPO Petrovax | Results Leading pulmonologists talk about latest advances in treatment options for post-COVID pulmonary fibrosis petrovax.com ↗
On day 180 of Longidaza administration, a trend toward an increase in forced vital capacity of the lungs (FVC) was noted in the study participants, and there were more patients with 10% better FVC values. |
| 2024-06-03 | NPO Petrovax | Results Experts discuss importance of combating antibiotic resistance at 26th IACMAC International Congress petrovax.com ↗
The professor cited the study which showed that Longidaza® disrupts biofilms, potentially enhancing the effectiveness of antibacterial drugs. |
| 2024-05-29 | NPO Petrovax | Results St. Petersburg and Nizhny Novgorod welcome Expert Breakfasts to talk on women's reproductive health petrovax.com ↗
The experts have presented the findings of the study showing that Longidaza® contributes to a lower pain syndrome and makes adhesions less prevalent. |
| 2024-03-19 | NPO Petrovax | Results Imoferaza® Application Research Results Revealed petrovax.com ↗
The research revealed positive effects: scars reduced significantly in patients as early as 4 weeks since they started applying the product. |
| 2023-10-24 | NPO Petrovax | Results Specialists talk about endometriosis at the All-Russian Congress “Innovations in obstetrics, gynecology and reproductive medicine” in Saint Petersburg petrovax.com ↗
Experts have presented the study results showing that Longidaza ® contributes to the reduction of pain severity and the prevalence of adhesions. |
| 2023-10-09 | NPO Petrovax | Results Longidaza®, a new option for treating pulmonary fibrosis, at the world academic community’s spotlight petrovax.com ↗
During the study it was shown that the use of Longidaza ® reduced pulmonary fibrosis, as evidenced by the improved histologic pattern of the lungs, reduced connective tissue buildup and lowered profibrotic factors in the pulmonary tissue. |
| 2023-09-28 | NPO Petrovax | Results Innovative post-COVID syndrome treatment options discussed in Kazakhstan petrovax.com ↗ |
| 2023-05-31 | NPO Petrovax | Results Doctors Speak on How to Defeat Chronic Prostatitis at the Scientific Aspects of Urological Practice Forum Held by the Russian Society of Urology petrovax.com ↗
Thus, according to one study [ 2 ] , the use of bovhyaluronidase azoximer reduces the content of biofilms by 50–60 %. |
| 2023-03-15 | NPO Petrovax | Results Bacterial prostatitis remains undiagnosed in 50% of cases petrovax.com ↗
When using bovhyaluronidase azoximer molecules (Longidaza ® ), the biofilm volume halved, whereas the patients’ condition returned to normal. |
| 2022-06-10 | NPO Petrovax | Results Health professionals discussed rehabilitation for patients recovered from COVID-19 petrovax.com ↗
According to the results of the DISSSOLVE [1, 2] study, patients in the medicine group, showed a more pronounced improvement in general physical condition, a decrease in the dyspnea severity, increase in physical activity tolerance |
| 2022-04-08 | NPO Petrovax | Results Post-COVID syndrome: treat, not ignore petrovax.com ↗
He told that in 44% of patients who recovered from COVID-19, the use of the medicine contributed to an increase in lung volume by more than 10%. |
| 2022-03-31 | NPO Petrovax | Results A new guide for doctors on COVID-19 vaccination in patients with comorbid diseases has been published petrovax.com ↗
The the drug has been shown to reduce dyspnea and increase tolerance to physical activity and oxygen saturation after COVID-19. |
| 2015-11-30 | NPO Petrovax | Regulatory WHO included a new Longidaze® INN into its register petrovax.com ↗
The WHO approved bovhyaluronidase azoximer as the INN for Longidaze ® developed by Petrovax Pharm 1 . |
All press releases naming this drug 22 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bovhyaluronidase azoximer | “Bovhyaluronidase azoximer for long-term pulmonary sequelae of COVID19: a multicenter, randomized, double-blind, placebo-controlled study.” PMID 42261259 ↗ Jun 2026 |
| Route | Intramuscular | “dose 3000 IU intramuscularly once every 5 days, 15 injections” NCT06383819 ↗ |